Healthcare

Vimian Group AB (publ)(VIMGF)

Live Price

Offline

$2.77

+0.00% today

1Y Change

-30.58%

Window

Jun 23, 2025 → Jun 17, 2026

Market Cap: $1.50B
Revenue Growth: +13.4%
EPS Growth: +71.5%
Dividend Yield: 0.0%

Coverage: 254 bars · Jun 23, 2025 → Jun 17, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Vimian Group AB (publ) (VIMGF) is a Healthcare stock with a market cap of $1.50B and listed on OTC. The stock last traded around $2.77 and down 30.6% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +13.4%, EPS growth of +71.5%, a dividend yield of 0.0%. What stands out right now is revenue +13.4%, EPS +71.5%, free cash flow +106.4% with operating margin 18.5% and ROIC 5.5%. Valuation already assumes a fairly strong business story at P/E 41.3 and price/sales 3.5. Stock Foundry combines VIMGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+13.4% vs +7.6% peer median

Operating Margin

Near sector median

+18.5% vs +19.4% peer median

P/E

Above sector median

41.3 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on Apr 29, 2026, but the surprise data is still limited.

The operating story is still moving forward

Revenue is running at +13.4% and EPS at +71.5%, with operating margin around 18.5%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.

View quarter-by-quarter reaction table

Quarter	EPS Δ	1D	5D	20D
2026 Apr 29, 2026	—	+0.0%	+0.0%	+0.0%
2026 Feb 12, 2026	-6.7%	+0.0%	+0.0%	+0.0%
2025 Oct 22, 2025	-41.4%	+0.0%	+0.0%	+0.0%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

VIMGF

—

Normalized return

SPY

—

S&P 500

Excess Return

—

Relative to SPY

VIMGF Max Drawdown

-35.58%

Trailing 1Y

SPY Max Drawdown

—

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for VIMGF and SPY.

Calendar-year return history is still loading or unavailable.

Company Overview

Vimian Group AB (publ)

Other OTC

Stockholm, SE

Visit vimian.com Call IR46 7 36 26 88 86

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.

Leadership: Alireza Tajbakhsh
IPO Date: Aug 22, 2022
Employees: 1.2k

Street Address: Riddargatan 19
Mailing: Stockholm, 11457
Region: Stockholm, SE

Reporting Currency: USD
Investor Line: 46 7 36 26 88 86
Last Updated: May 5, 2026

ISIN: SE0015961982

Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E: 41.3
EV/EBITDA: 15.2
Price/Sales: 3.5
Price/Book: 2.1

Growth

Revenue: +13.4%
EPS: +71.5%
Free Cash Flow: +106.4%

Profitability

Gross Margin: 55.7%
Operating Margin: 18.5%
Net Margin: 8.5%
ROE: 5.2%
ROIC: 5.5%

Balance Sheet

Debt/Equity: 0.34
Current Ratio: 1.71

Earnings Reports

📅 Last reportedApr 29, 2026

Period	B/M	EPS	EPS Δ	Revenue	Rev Δ
— Apr 29, 26		— Est 0.03	—	— Est 131073.4B	—
— Feb 12, 26	✗	0.02 Est 0.03	-6.7%	128021.6B Est 126819.6B	+0.9%
— Oct 22, 25	✗	0.01 Est 0.02	-41.4%	122161.4B Est 107861.0B	+13.3%
— Jul 18, 25	✗	0.02 Est 0.03	-38.8%	122807.0B Est 103646.9B	+18.5%
— Apr 29, 25	✗	0.01 Est 0.02	-63.4%	107500.0B Est 109898.7B	-2.2%
— Feb 13, 25	✗	0.02 Est 0.02	-6.9%	104900.0B Est 98360.9B	+6.7%
— Oct 24, 24	✗	-0.00 Est 0.02	-117.5%	87646.0B Est 97418.0B	-10.0%
— Aug 15, 24	✗	0.01 Est 0.02	-57.2%	90992.0B Est 96335.4B	-5.5%
— May 2, 24	✗	0.01 Est 0.03	-72.5%	91299.0B Est 101346.1B	-9.9%
— Feb 15, 24	✗	-0.01 Est 0.01	-229.4%	82456.0B Est 93118.5B	-11.4%
— Sep 30, 23	✓	0.02 Est 0.01	+18.5%	79878.0B Est 82120.0B	-2.7%
— Jun 30, 23	✗	0.01 Est 0.01	-46.9%	81311.0B Est 83187.1B	-2.3%
— Mar 31, 23	✗	0.01 Est 0.03	-57.7%	88084.0B Est 91355.0B	-3.6%
— Mar 8, 23	✗	-0.04 Est 0.05	-180.0%	75455.0B Est 78903.8B	-4.4%
— Nov 16, 22	✗	0.01 Est 0.03	-66.7%	70884.0B Est 67067.2B	+5.7%
— Aug 24, 22	✓	0.04 Est 0.03	+33.3%	67028.0B Est 68330.1B	-1.9%

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official

No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guide Read how to compare stocks